Overview

• Biotech firm's Q4 revenue missed analyst expectations

• Net income for Q4 rises compared to last year

• Company repurchased $1 bln of common stock in August 2025

Outlook

• United Therapeutics anticipates pivotal data from ADVANCE OUTCOMES and TETON-1 trials

• Company expects continued double-digit revenue growth

Result Drivers

• TYVASO DPI GROWTH - Significant revenue growth driven by increased sales of Tyvaso DPI, attributed to more patients and Medicare Part D benefit redesign

• ORENITRAM SALES INCREASE - Orenitram revenues grew due to increased quantities sold, influenced by Medicare Part D benefit redesign

• NEBULIZED TYVASO DECLINE - Decline in Nebulized Tyvaso sales due to decreased quantities sold

Company press release: ID:nBw6YsyZLa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for United Therapeutics Corp is $525.00, about 10.9% above its February 24 closing price of $473.43

• The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)